Morgan Stanley’s Impact BioMedical IBO Stock Holding History

Morgan Stanley’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.27K	Buy	9,285 +11	+0.1%	+$7	﹤0.01%	7247
2026 Q1	$5.56K	Buy	9,274 +8	+0.1%	+$4	﹤0.01%	7111
2025 Q4	$4.68K	Hold	9,266	–	–	﹤0.01%	7080
2025 Q3	$6.16K	Buy	+9,266	New	+$5.84K	﹤0.01%	7038
2025 Q2	–	Sell	-7,800	Closed	-$6.79K	–	8311
2025 Q1	$6.79K	Buy	+7,800	New	+$13.5K	﹤0.01%	6913
2024 Q4	–	Sell	-58	Closed	-$116	–	8133
2024 Q3	$116	Buy	+58	New	+$137	﹤0.01%	7423

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley's IBO Position: Q2 2026 in Review

Morgan Stanley increased its Impact BioMedical (IBO) stake by 0.12% in Q2 2026, buying an estimated $7 and bringing the position to 9,285 shares worth $4.27K. The position accounts for ﹤0.01% of the portfolio, ranked #7247.

Morgan Stanley first reported a position in IBO in Q3 2024 and has held it in 6 quarters since. The position peaked at $6.79K in Q1 2025. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

Morgan Stanley held 9,285 shares of Impact BioMedical worth $4.27K as of Q2 2026.
Morgan Stanley bought 11 Impact BioMedical shares in Q2 2026, an estimated $7.
Impact BioMedical made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7247 holding.
Morgan Stanley first reported a position in Impact BioMedical in Q3 2024 and has held it in 6 quarters since.
Morgan Stanley's Impact BioMedical position peaked at $6.79K in Q1 2025.
22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.